ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CLIN Clinigen Group Plc

925.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Clinigen Group Plc LSE:CLIN London Ordinary Share GB00B89J2419 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 925.00 924.50 925.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Clinigen Share Discussion Threads

Showing 651 to 675 of 1400 messages
Chat Pages: Latest  32  31  30  29  28  27  26  25  24  23  22  21  Older
DateSubjectAuthorDiscuss
24/4/2015
11:25
Video interview with CEO Peter George



Peter George, chief executive of Clinigen (LON:CLIN), says the £225mln acquisition of competitor Idis gives it access to the US$2.2bln ethical unlicensed medicine market. Synergy savings of £2.5mln have been identified in the deal which makes the specialty pharma company the global leader in unlicensed medicines. George tells Proactive Investors profit will be driven through the gross profit line much faster than synergy savings. “This is about a growth plan not a cost savings plan. We want to hit the ground running and take the market by storm.”
The deal achieves the second of Clinigen’s four strategic goals which include becoming global leader in both clinical trials supply and unlicensed medicines. George says Clinigen wants to grow its portfolio from five to ten products and improve its global footprint by looking at the Southern hemisphere.

proactivest
24/4/2015
09:59
Slogweep - just a small correction. new shares placed is 27m; existing shares = 125m. So percentage new raised = 22%. But your point is still valid.
ramridge
24/4/2015
09:30
very tempted to add,just wondering if we will have a pull back
gucci
24/4/2015
09:25
I did a back of the envelope and seems to be circa 9% EBITDA per share enhancing in 2015 (I ignored both synergies and higher interest costs).

Looks very good.

hutch_pod
24/4/2015
09:05
Glad I didn't sell down any of these to part-fund my Opay rights!
lomax99
24/4/2015
08:45
well done AISHAH
gucci
24/4/2015
08:45
Numis, BUY - ups target to 860p
aishah
24/4/2015
08:05
That's a whopper! Take a bow SCSW - I bought in at £1.83p in 2012. Run your winners imo.
aishah
24/4/2015
07:35
im sure Jim Slatter will be commenting in his next update in Telegraph soon
gucci
24/4/2015
07:31
Share capital increase by 50% in a discounted placing - shareholders shut out again!

Why not have a rights issue - It should be compulsory to have a rights issue if the new shares issued exceed 10% of those already in issue, with a moratorium on further issues within 12 months.

slogsweep
24/4/2015
07:28
Damn,
I was waiting for 500p to increase. Fat chance now - I hate it when this happens.
apad

apad
24/4/2015
07:26
Have done -- this is adding massive potential!
ddav
24/4/2015
07:26
Looks like a great deal.
Didnt get filled this morning so topup on next pullback.

phowdo
24/4/2015
07:16
perfect
time to add imo

gucci
24/4/2015
06:56
That looks a very interesting acquisition:

will become the market leader

Immediately earnings enhancing

significantly earnings enhancing in its full year

further earnings enhancing in future years.

cfro
15/4/2015
12:25
Not bosom-buddies i hope though, gucci! :-/
cfro
15/4/2015
11:00
:-) yes we are buddies
gucci
15/4/2015
10:19
Hi gucci, we seem to be bumping into each alot lately. :-)

Nice steady gains here over last few days. Happy to be patient and await drug acquisition news. Cant be too far away now i wouldn't have thought.

cfro
15/4/2015
09:45
good looking chart
gucci
27/3/2015
16:08
Looking to break out
gucci
27/3/2015
15:02
To view Clinigen's presentation from last night's Proactive Investors One2One Investor Forum, click on the following link:
aim_trader
26/3/2015
11:45
A reminder that Shaun Chilton, COO will be presenting tonight at the Chesterfield, Mayfair. To register click here:
aim_trader
20/3/2015
10:01
lets hope for new highs soon
gucci
20/3/2015
09:58
Sp flying back up now....

Just shows how quickly this can move in either direction. Quite a volatile share at times.

cfro
20/3/2015
08:33
Clin Clinigen Broker Views...........

Clinigen Group broker views

Date Broker Recommendation Price Old target price New target price Notes

11 Mar N+1 Singer Buy 527.00 590.00 590.00 Retains
03 Mar Investec Hold 527.00 546.00 - Under Review
03 Mar Numis Buy 527.00 650.00 770.00 Reiterates

mike740
Chat Pages: Latest  32  31  30  29  28  27  26  25  24  23  22  21  Older

Your Recent History

Delayed Upgrade Clock